Evidence for a Role of Frataxin in Pancreatic Islets Isolated from Multi-Organ Donors with and Without Type 2 Diabetes Mellitus

 

 Buy Article Permissions and Reprints

Abstract

Frataxin (FXN) is a mitochondrial protein involved in iron metabolism and in the modulation of reactive oxygen and/or nitrogen species production. No information is currently available as for the role of frataxin in isolated human pancreatic islets. We studied islets from pancreases of multi-organ donors with (T2DM) and without (Ctrl) Type 2 diabetes mellitus. In these islets, we determined FXN gene and protein expression by qualitative and quantitative Real-Time RT-PCR, nitrotyrosine concentration, and insulin release in response to glucose stimulation (SI). FXN gene and protein were expressed in human islets, though the level of expression was much lower in T2DM islets. The latter also had lower insulin release and higher concentration of nitrotyrosine. A positive correlation was apparent between SI and FXN gene expression, while a negative correlation was found between nitrotyrosine islet concentration and FXN expression. Transfection of Ctrl islets with siRNA FXN caused reduction of FXN expression, increase of nitrotyrosine concentration, and reduction of insulin release. In conclusion, in human pancreatic islets FXN contributes to regulation of oxidative stress and insulin release in response to glucose. In islets from T2DM patients FXN expression is reduced while oxidative stress is increased and insulin release in response to glucose impaired.

• References

• 1 Pandolfo M. Iron metabolism and mitochondrial abnormalities in Friedreich ataxia. Blood Cells Mol Dis 2002; 29: 536-547
  CrossrefPubMedGoogle Scholar
• 2 Tan G, Chen LS, Lonnerdal B, Gellera C, Taroni FA, Cortopassi GA. Frataxin expression rescues mitochondrial dysfunctions in FRDA cells. Hum Mol Genet 2001; 10: 2099-2107
  CrossrefPubMedGoogle Scholar
• 3 Cossée M, Puccio H, Gansmuller A, Koutnikova H, Dierich A, LeMeur M, Fischbeck K, Dollé P, Koenig M. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet 2000; 9: 1219-1226
  CrossrefPubMedGoogle Scholar
• 4 Lee DW, Andersen JK, Kaur D. Iron dysregulation and neurodegeneration: the molecular connection. Mol Interv 2006; 6: 89-97
  CrossrefPubMedGoogle Scholar
• 5 Calabrese V, Lodi R, Tonon C, D’Agata V, Sapienza M, Scapagnini G, Mangiameli A, Pennisi G, Stella AM, Butterfield DA. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich’s ataxia. J Neurol Sci 2005; 233: 145-162
  CrossrefPubMedGoogle Scholar
• 6 Schulz JB, Dehmer T, Schöls L, Mende H, Hardt C, Vorgerd M, Bürk K, Matson W, Dichgans J, Beal MF. Oxidative stress in patients with Friedreich ataxia. Neurology 2000; 55: 1719-1721
  CrossrefPubMedGoogle Scholar
• 7 Gakh O, Park S, Liu G, Macomber L, Imlay JA, Ferreira GC, Isaya G. Mitochondrial iron detoxification is a primary function of FXN that limits oxidative damage and preserves cell longevity. Hum Mol Genet 2006; 15: 467-479
  PubMedGoogle Scholar
• 8 Chantrel-Groussard K, Geromel V, Puccio H, Koenig M, Munnich A, Rötig A, Rustin P. Disabled early recruitment of antioxidant defenses in Friedreich’s ataxia. Hum Mol Genet 2001; 10: 2061-2067
  CrossrefPubMedGoogle Scholar
• 9 Shoichet SA, Bäumer AT, Stamenkovic D, Sauer H, Pfeiffer AF, Kahn CR, Müller-Wieland D, Richter C, Ristow M. FXN promotes antioxidant defences in a thiol-dependent manner resulting in diminished malignant transformation in vitro. Hum Mol Genet 2002; 11: 815-821
  CrossrefPubMedGoogle Scholar
• 10 Finocchiaro G, Baio G, Micossi P, Pozza G, di Donato S. Glucose metabolism alterations in Friedreich’s ataxia. Neurology 1998; 38: 1292-1296
  PubMedGoogle Scholar
• 11 Ristow M, Giannakidou E, Hebinck J, Busch K, Vorgerd M, Kotzka J, Knebel B, Mueller-Berghaus J, Epplen C, Pfeiffer A, Kahn CR, Doria A, Krone W, Mueller-Wieland D. An association between NIDDM and a GAA trinucleotide repeat polymorphism in the X25/frataxin (Friedreich’s ataxia) gene. Diabetes 1998; 47: 851-854
  CrossrefPubMedGoogle Scholar
• 12 Dupont S, Dubois D, Vionnet N, Boitard C, Caillat-Zucman S, Timsit J, Froguel P. No association between the Friedreich’s ataxia gene and NIDDM in the French population. Diabetes 1998; 47: 1654-1656
  CrossrefPubMedGoogle Scholar
• 13 Dalgaard LT, Hansen T, Urhammer SA, Clausen JO, Eiberg H, Pedersen O. Intermediate expansions of a GAA repeat in the frataxin gene are not associated with type 2 diabetes or altered glucose-induced beta-cell function in Danish Caucasians. Diabetes 1999; 48: 914-917
  CrossrefPubMedGoogle Scholar
• 14 t Hart LM, Ruige JB, Dekker JM, Stehouwer CD, Maassen JA, Heine R. Altered beta-cell characteristics in impaired glucose tolerant carriers of a GAA trinucleotide repeat polymorphism in the frataxin gene. Diabetes 1999; 48: 924-926
  CrossrefPubMedGoogle Scholar
• 15 Holmkvist J, Almgren P, Parikh H, Zucchelli M, Kere J, Groop L, Lindgren CM. Haplotype construction of the FRDA gene and evaluation of its role in type II diabetes. Eur J Hum Genet 2005; 13: 849-855
  CrossrefPubMedGoogle Scholar
• 16 Lynn S, Hattersley AT, McCarthy MI, Frayling TM, Turnbull DM, Walker M. Intermediate expansions of a X25/frataxin gene GAA repeat and type II diabetes: assessment using parent-offspring trios. Diabetologia 2000; 43: 384-385
  CrossrefPubMedGoogle Scholar
• 17 Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 2004; 279: 42351e4
  PubMedGoogle Scholar
• 18 Tews D, Lehr S, Hartwig S, Osmers A, Paslack W, Eckel J. Anti-apoptotic action of exendin-4 in INS-1 beta cells: comparative protein pattern analysis of isolated mitochondria. Horm Metab Res 2009; 41: 294-301
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Kawasaki Y, Harashima S, Sasaki M, Mukai E, Nakamura Y, Harada N, Toyoda K, Hamasaki A, Yamane S, Yamada C, Yamada Y, Seino Y, Inagaki N. Exendin-4 protects pancreatic beta cells from the cytotoxic effect of rapamycin by inhibiting JNK and p38 phosphorylation. Horm Metab Res 2010; 42: 311-317
  Article in Thieme ConnectPubMedGoogle Scholar
• 20 Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006; 212: 167-178
  CrossrefPubMedGoogle Scholar
• 21 Wu L, Nicholson W, Knobel SM, Steffner RJ, May JM, Piston DW, Powers AC. Oxidative stress is a mediator of glucose toxicity in insulin-secreting pancreatic islet cell lines. J Biol Chem 2004; 279: 12126-1234
  PubMedGoogle Scholar
• 22 D’Aleo V, Del Guerra S, Martano M, Bonamassa B, Canistro D, Soleti A, Valgimigli L, Paolini M, Filipponi F, Boggi U, Del Prato S, Lupi R. The non-peptidyl low molecular weight radical scavenger IAC protects human pancreatic islets from lipotoxicity. Mol Cell Endocrinol 2009; 309: 63-66
  CrossrefPubMedGoogle Scholar
• 23 Del Guerra S, Lupi R, D’Aleo V, Filipponi F, Boggi U, Marchetti P. Glucose transporter 2 gene polymorphisms and beta-cell function in isolated human pancreatic islets. Diabetes Metab 2009; 35: 155-156
  CrossrefPubMedGoogle Scholar
• 24 Lupi R, Del Guerra S, Bugliani M, Boggi U, Mosca F, Torri S, Del Prato S, Marchetti P. The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur J Endocrinol 2006; 154: 355-361
  CrossrefPubMedGoogle Scholar
• 25 Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, Sjögren M, Ling C, Eriksson KF, Lethagen AL, Mancarella R, Berglund G, Tuomi T, Nilsson P, Del Prato S, Groop L. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007; 117: 2155-2163
  CrossrefPubMedGoogle Scholar
• 26 Wilson RB. FXN and FXN deficiency in Friedreich’s ataxia. J Neurol Sci 2003; 207: 103-105
  CrossrefPubMedGoogle Scholar
• 27 Condò I, Ventura N, Malisan F, Tomassini B, Testi R. A pool of extra mitochondrial FXN that promotes cell survival. J Biol Chem 2006; 281: 16750-16756
  CrossrefPubMedGoogle Scholar
• 28 Ristow M, Mulder H, Pomplun D, Schulz TJ, Müller-Schmehl K, Krause A, Fex M, Puccio H, Müller J, Isken F, Spranger J, Müller-Wieland D, Magnuson MA, Möhlig M, Koenig M, Pfeiffer AF. FXN deficiency in pancreatic islets causes diabetes due to loss of beta cell mass. J Clin Invest 2003; 112: 527-534
  CrossrefPubMedGoogle Scholar
• 29 Pandolfo M. Frataxin deficiency and mitochondrial dysfunction. Mitochondrion 2002; 2: 87-93
  CrossrefPubMedGoogle Scholar
• 30 Runko AP, Griswold AJ, Min KT. Overexpression of frataxin in the mitochondria increases resistance to oxidative stress and extends lifespan in Drosophila. FEBS Lett 2008; 582: 715-719
  CrossrefPubMedGoogle Scholar
• 31 Ling C, Del Guerra S, Lupi R, Rönn T, Granhall C, Luthman H, Masiello P, Marchetti P, Groop L, Del Prato S. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 2008; 51: 615-622
  CrossrefPubMedGoogle Scholar
• 32 D’Adamo M, Perego L, Cardellini M, Marini MA, Frontoni S, Andreozzi F, Sciacqua A, Lauro D, Sbraccia P, Federici M, Paganelli M, Pontiroli AE, Lauro R, Perticone F, Folli F, Sesti G. The − 866A/A genotype in the promoter of the human uncoupling protein 2 gene is associated with insulin resistance and increased risk of type 2 diabetes. Diabetes 2004; 53: 1905-1910
  CrossrefPubMedGoogle Scholar
• 33 Del Guerra S, Lupi R, Marselli L, Masini M, Bugliani M, Sbrana S, Torri S, Pollera M, Boggi U, Mosca F, Del Prato S, Marchetti P. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 2005; 54: 727-735
  CrossrefPubMedGoogle Scholar
• 34 Bonora E. Protection of pancreatic beta-cells: is it feasible?. Nutr Metab Cardiovasc Dis 2008; 18: 74-83
  CrossrefPubMedGoogle Scholar
• 35 Barroso I, Luan J, Sandhu MS, Franks PW, Crowley V, Schafer AJ, O’Rahilly S, Wareham NJ. Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia 2006; 49: 501-505
  CrossrefPubMedGoogle Scholar